Skip to content
Clinical Trials – home

Dextran 70: A Versatile Medical Treatment

1 / 2
trials open to patients / all trials
13+
Countries

In short

Dextran 70, a plasma expander, is being studied in various clinical trials for its potential benefits in treating different medical conditions. This article explores the use of Dextran 70 in clinical research, focusing on its applications in liver cirrhosis, cardiac surgery, eye disorders, and other areas. We'll examine how this compound is being investigated to improve patient outcomes and address specific medical challenges.

What is Dextran 70?

Dextran 70 is a medical compound used in various treatments. It is a type of plasma expander, which means it helps increase the volume of blood in your body. Dextran 70 is also known by other names, including: Dextran 70 6% in 0.9% Sodium Chloride Dextran 70 6% in 5% Dextrose Gentran 70 Hyskon These alternative names may be used by healthcare providers or in medical literature.

Uses of Dextran 70

Dextran 70 is used to treat various medical conditions, including:

  • Spontaneous Bacterial Peritonitis (SBP): This is an infection in the abdominal cavity that can occur in patients with liver cirrhosis. Dextran 70 is being studied as a potential alternative to human albumin in treating this condition.
  • Cardiac Surgery in Children: Dextran 70 is being investigated for use during heart surgeries in young children to help reduce inflammation and fluid buildup.
  • Eye Treatments: In some eye surgeries and treatments, Dextran 70 is used as part of eye drop solutions.
  • Liver Cirrhosis and Kidney Problems: Researchers are studying whether Dextran 70 can help patients with liver cirrhosis who develop kidney issues.

How Dextran 70 Works

Dextran 70 works by expanding the volume of plasma (the liquid part of blood) in your body. This can be helpful in several ways:

  • It can help maintain blood pressure and improve blood flow to organs.
  • In heart surgeries, it may help reduce inflammation and prevent excess fluid from leaking out of blood vessels.
  • When used in eye treatments, it can help maintain the proper consistency of eye drop solutions.

Administration

Dextran 70 is typically given intravenously (through a vein). The dose and duration of treatment can vary depending on the specific condition being treated and the patient's individual needs. For example:

  • In studies for spontaneous bacterial peritonitis, patients received 1.0 g/kg of Dextran 70 daily for three days.
  • For cardiac surgery in children, a solution of 7.5% sodium chloride (salt) in 6% Dextran 70 was used.
  • In eye treatments, Dextran 70 may be part of an eye drop solution.

Potential Side Effects

While Dextran 70 is generally considered safe when used as directed, it can have some side effects. These may include:

  • Allergic reactions
  • Changes in blood clotting
  • Fluid overload (too much fluid in the body)

It's important to discuss potential risks and side effects with your healthcare provider before starting any treatment with Dextran 70.

Ongoing Research

Researchers are continually studying new ways to use Dextran 70. Some areas of current research include:

  • Comparing Dextran 70 to human albumin in treating spontaneous bacterial peritonitis.
  • Using Dextran 70 in heart surgeries for young children to reduce inflammation and fluid buildup.
  • Investigating whether Dextran 70 can help patients with liver cirrhosis who develop kidney problems.

These ongoing studies aim to better understand how Dextran 70 can be used to improve patient outcomes in various medical conditions.

Questions people often ask

Conditions where Dextran 70 is being studied

Each condition opens its own overview and trial list

Trials with Dextran 70

Recruiting trials first

See all 2 →
Quick filters
  • Participants:Adults
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).